Trial · NCT07892417
Parasacral TENS Project
NCT07892417, Not applicable, Not yet recruiting, University of Virginia
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Parasacral TENS Project. Trials, record NCT07892417. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07892417
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Parasacral TENS Project
- NCT number
- NCT07892417
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 60 participants, estimated
- Lead sponsor
- University of Virginia
- Conditions
- Overactive Bladder (OAB), Lower Urinary Tract Dysfunction
- Interventions
- Parasacral transcutaneous electric nerve stimulation (TENS), Oxybutynin
- First posted
- 2026-10-23
- Last updated
- 2026-10-23
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Efficacy of TENS | baseline to completion of treatment (week 12) | The primary endpoint is the change from baseline to 12 weeks in the Vancouver Nonneurogenic Lower Urinary Tract Dysfunction/Dysfunctional Elimination Syndrome (NLUTD/DES) Symptom Score (VSS), a validated composite score ranging from 0-54. |
| Secondary | Voiding Diary | baseline to completion of treatment (week 12) | frequency of voids and incontinence episodes per 24 hours |
| Secondary | Comparison of Uroflowmetry changes from baseline to completion of treatment (week 12) | baseline to completion of treatment (week 12) | A uroflow test will be performed at baseline and completion of the treatment to evaluate changes in uroflow patterns. Uroflowmetry measure the volume, time, and strength of urine flow and converts it into a graph so it can be compared against a normal for age and sex. It can also be used to evaluate changes in voiding patterns in the same person over time. The outcome measures will be: * Pre-void bladder volume * Post-void bladder volume * Flow Curve Pattern * Time to Max Flow * Max Flow Rate * Average Flow Rate * Voided Volume * Franco Flow Index * EMG Used: yes/no If yes: EMG lag time present: yes/no EMG activation during voiding: yes/no |
| Secondary | Patient Questionnaires | baseline to completion of treatment (week 12) | Questionnaires will assess treatment adherence, perceived importance of medication use, ease of treatment administration, symptom relief, quality of life, treatment preferences, and treatment tolerability. Individual questionnaire items are scored using ordinal scales ranging from 1 to 4 or 1 to 5, depending on the assessment domain. For treatment adherence and ease of use, higher scores indicate less favorable outcomes, including poorer treatment adherence and greater difficulty administering treatment. For quality of life, higher scores indicate more favorable outcomes. Higher medication-use importance scores reflect a greater preference for avoiding or reducing medication use and do not directly represent clinical improvement. The symptom relief only uses yes/no answers, so this cannot be scaled. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers14
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07892417
GET https://conductscience.org/api/trials/v1/NCT07892417/registered